1 PD-1 Inhibitor Market Overview
1.1 Product Overview and Scope of PD-1 Inhibitor
1.2 Classification of PD-1 Inhibitor by Types
1.2.1 Global PD-1 Inhibitor Revenue Comparison by Types (2020-2025)
1.2.2 Global PD-1 Inhibitor Revenue Market Share by Types in 2018
1.2.3 Pembrolizumab
1.2.4 Nivolumab
1.2.5 Atezolizumab
1.2.6 Durvalumab
1.2.7 Avelumab
1.2.8 Other
1.3 Global PD-1 Inhibitor Market by Application
1.3.1 Global PD-1 Inhibitor Market Size and Market Share Comparison by Applications (2015-2025)
1.3.2 Melanoma
1.3.3 Non-small Cell Lung Cancer (NSCLC)
1.3.4 Urothelial Carcinoma
1.3.5 Classical Hodgkin Lymphoma
1.3.6 Renal Cell Carcinoma
1.3.7 Other
1.4 Global PD-1 Inhibitor Market by Regions
1.4.1 Global PD-1 Inhibitor Market Size (Million USD) Comparison by Regions (2015-2025)
1.4.1 North America (USA, Canada and Mexico) PD-1 Inhibitor Status and Prospect (2015-2025)
1.4.2 Europe (Germany, France, UK, Russia and Italy) PD-1 Inhibitor Status and Prospect (2015-2025)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) PD-1 Inhibitor Status and Prospect (2015-2025)
1.4.4 South America (Brazil, Argentina, Colombia) PD-1 Inhibitor Status and Prospect (2015-2025)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) PD-1 Inhibitor Status and Prospect (2015-2025)
1.5 Global Market Size of PD-1 Inhibitor (2015-2025)
2 Manufacturers Profiles
2.1 Merck
2.1.1 Business Overview
2.1.2 PD-1 Inhibitor Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 Merck PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2019)
2.2 Novartis
2.2.1 Business Overview
2.2.2 PD-1 Inhibitor Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2019)
2.3 Onxeo
2.3.1 Business Overview
2.3.2 PD-1 Inhibitor Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 Onxeo PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2019)
2.4 Sumitomo Dainippon Pharma
2.4.1 Business Overview
2.4.2 PD-1 Inhibitor Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Sumitomo Dainippon Pharma PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2019)
2.5 Taiwan Liposome Company
2.5.1 Business Overview
2.5.2 PD-1 Inhibitor Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Taiwan Liposome Company PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2019)
2.6 Tiziana Life Sciences
2.6.1 Business Overview
2.6.2 PD-1 Inhibitor Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Tiziana Life Sciences PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2019)
2.7 Genentech (Roche)
2.7.1 Business Overview
2.7.2 PD-1 Inhibitor Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Genentech (Roche) PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2019)
2.8 AstraZeneca
2.8.1 Business Overview
2.8.2 PD-1 Inhibitor Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 AstraZeneca PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2019)
2.9 Pfizer
2.9.1 Business Overview
2.9.2 PD-1 Inhibitor Type and Applications
2.9.2.1 Product A
2.9.2.2 Product B
2.9.3 Pfizer PD-1 Inhibitor Revenue, Gross Margin and Market Share (2017-2019)
3 Global PD-1 Inhibitor Market Competition, by Players
3.1 Global PD-1 Inhibitor Revenue and Share by Players (2015-2019)
3.2 Market Concentration Rate
3.2.1 Top 5 PD-1 Inhibitor Players Market Share
3.2.2 Top 10 PD-1 Inhibitor Players Market Share
3.3 Market Competition Trend
4 Global PD-1 Inhibitor Market Size by Regions
4.1 Global PD-1 Inhibitor Revenue and Market Share by Regions
4.2 North America PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
4.3 Europe PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
4.4 Asia-Pacific PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
4.5 South America PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
4.6 Middle East and Africa PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
5 North America PD-1 Inhibitor Revenue by Countries
5.1 North America PD-1 Inhibitor Revenue by Countries (2015-2019)
5.2 USA PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
5.3 Canada PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
5.4 Mexico PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
6 Europe PD-1 Inhibitor Revenue by Countries
6.1 Europe PD-1 Inhibitor Revenue by Countries (2015-2019)
6.2 Germany PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
6.3 UK PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
6.4 France PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
6.5 Russia PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
6.6 Italy PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
7 Asia-Pacific PD-1 Inhibitor Revenue by Countries
7.1 Asia-Pacific PD-1 Inhibitor Revenue by Countries (2015-2019)
7.2 China PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
7.3 Japan PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
7.4 Korea PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
7.5 India PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
7.6 Southeast Asia PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
8 South America PD-1 Inhibitor Revenue by Countries
8.1 South America PD-1 Inhibitor Revenue by Countries (2015-2019)
8.2 Brazil PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
8.3 Argentina PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
8.4 Colombia PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
9 Middle East and Africa Revenue PD-1 Inhibitor by Countries
9.1 Middle East and Africa PD-1 Inhibitor Revenue by Countries (2015-2019)
9.2 Saudi Arabia PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
9.3 UAE PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
9.4 Egypt PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
9.5 Nigeria PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
9.6 South Africa PD-1 Inhibitor Revenue and Growth Rate (2015-2019)
10 Global PD-1 Inhibitor Market Segment by Type
10.1 Global PD-1 Inhibitor Revenue and Market Share by Type (2015-2019)
10.2 Global PD-1 Inhibitor Market Forecast by Type (2020-2025)
10.3 Pembrolizumab Revenue Growth Rate (2015-2025)
10.4 Nivolumab Revenue Growth Rate (2015-2025)
10.5 Atezolizumab Revenue Growth Rate (2015-2025)
10.6 Durvalumab Revenue Growth Rate (2015-2025)
10.7 Avelumab Revenue Growth Rate (2015-2025)
10.8 Other Revenue Growth Rate (2015-2025)
11 Global PD-1 Inhibitor Market Segment by Application
11.1 Global PD-1 Inhibitor Revenue Market Share by Application (2015-2019)
11.2 PD-1 Inhibitor Market Forecast by Application (2020-2025)
11.3 Melanoma Revenue Growth (2015-2019)
11.4 Non-small Cell Lung Cancer (NSCLC) Revenue Growth (2015-2019)
11.5 Urothelial Carcinoma Revenue Growth (2015-2019)
11.6 Classical Hodgkin Lymphoma Revenue Growth (2015-2019)
11.7 Renal Cell Carcinoma Revenue Growth (2015-2019)
11.8 Other Revenue Growth (2015-2019)
12 Global PD-1 Inhibitor Market Size Forecast (2020-2025)
12.1 Global PD-1 Inhibitor Market Size Forecast (2020-2025)
12.2 Global PD-1 Inhibitor Market Forecast by Regions (2020-2025)
12.3 North America PD-1 Inhibitor Revenue Market Forecast (2020-2025)
12.4 Europe PD-1 Inhibitor Revenue Market Forecast (2020-2025)
12.5 Asia-Pacific PD-1 Inhibitor Revenue Market Forecast (2020-2025)
12.6 South America PD-1 Inhibitor Revenue Market Forecast (2020-2025)
12.7 Middle East and Africa PD-1 Inhibitor Revenue Market Forecast (2020-2025)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
